• Curasight resumed patient enrollment in its Phase 1 glioblastoma study following clearance of a protocol amendment.
• The revised trial design drops mannitol-induced blood-brain barrier disruption for newly enrolled patients receiving uTREAT.
• No clinical results have been presented yet; topline Phase 1 data are expected in H1 2027.
• The change aims to support a more robust dataset to guide later dose-finding and Phase 2 development decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curasight A/S published the original content used to generate this news brief via Cision (Ref. ID: 20261005:BIT:8912:0) on October 05, 2026, and is solely responsible for the information contained therein.